Patents Issued in September 15, 2020
-
Patent number: 10772816Abstract: Disclosed herein are compositions suitable for styling hair. Certain compositions comprise a. at least one alkoxysilane having at least one solubilizing functional group and at least one amino substituent; b. at least one acid; and c. at least one ionic latex film former. Also provided are methods of using same.Type: GrantFiled: December 27, 2017Date of Patent: September 15, 2020Assignee: L'OREALInventors: Nghi Van Nguyen, Jim Mitchell Singer, Siliu Tan, Aditi Gogineni
-
Patent number: 10772817Abstract: An aqueous cleansing composition comprising a cationic surfactant, a nonionic surfactant, and a thickener comprising an alkoxylated methyl glucose ether, wherein a weight ratio of cationic surfactant to nonionic surfactant is greater than 0.9:1. The combination of the cationionic:nonionic surfactant ratio with the alkoxylated methyl glucose ether thickener provides the composition with cold weather stability. Cold weather stability is observed when the composition remains transparent after cold storage.Type: GrantFiled: June 21, 2019Date of Patent: September 15, 2020Assignee: Colgate-Palmolive CompanyInventors: Eugene Hardy, Marian Holerca, Rabab Ahmed, Evangelia Arvanitidou
-
Patent number: 10772818Abstract: The instant disclosure relates to methods and kits for artificially coloring hair and improving the durability of the artificially colored hair. The methods include: (I) combining an antioxidant booster composition, a hair coloring base composition, and a developer composition to form an antioxidant-enriched hair coloring composition within 2 hours of application to the hair; (II) applying the antioxidant enriched hair coloring composition to the hair and allowing the antioxidant enriched hair coloring composition to remain on the hair for a period of time; and (III) rinsing the antioxidant enriched hair coloring composition from the hair. The antioxidant booster composition can be included in a kit with a hair coloring base composition and/or a developer composition, wherein the antioxidant booster composition, the coloring base composition, and the developer composition are separately contained.Type: GrantFiled: October 24, 2018Date of Patent: September 15, 2020Assignee: L'OREALInventors: Michael DeGeorge, Minnie Chan, Jim Singer, Daniella Gonzalez-Toro, Jeffrey Wang, Lisa Jablonski, Martin Asare
-
Patent number: 10772819Abstract: The invention relates to a process for treating keratin fibres, in particular human keratin fibres such as the hair, comprising: •(i) a step of applying an oxidized polysaccharide, •(ii) a step of heating to a temperature of at least 100° C., •(iii) a step of applying a compound (I) •Ri—CHOH—CH(NH—COY)(CH2OH) (I). The invention also relates to a cosmetic composition comprising an oxidized polysaccharide and a compound (I) for which Y?H and to kits. The process makes it possible to obtain good hair-conditioning cosmetic properties, with a long-lasting effect.Type: GrantFiled: September 11, 2014Date of Patent: September 15, 2020Assignee: L'OREALInventors: Nawel Baghdadli, Isabelle Pasini
-
Patent number: 10772820Abstract: Disclosed is a composition for cleansing a keratin material, comprising, in an aqueous phase: a) at least one amino acid surfactant; b) calcium alginate, wherein the weight ration (a/b) of a) amino acid surfactant and b) calcium alginate is from 0.7 to 6.Type: GrantFiled: July 22, 2015Date of Patent: September 15, 2020Assignee: L'OREALInventor: Huifeng Wang
-
Patent number: 10772821Abstract: An oral composition is described. The oral composition can include a solvent having water and a cosolvent chosen from lower alkyl alcohols and acetone; a basic copolymer having basic acrylate monomeric units, basic methacrylate monomeric units, or a combination thereof; no less than 0.5 wt-% of an acid buffering or neutralizing agent; and optionally an active agent. The oral composition can include from about 6° to about 15° wt % of water, from about 30° to about 80° wt % of the cosolvent, and from about 25 to about 55° wt-% of the basic copolymer. The basic copolymer can be dissolved in the oral composition, the oral composition is capable of forming a film on a surface when contacted with an aqueous solution; and the wt-% of each component is based on the total weight of the composition.Type: GrantFiled: September 27, 2019Date of Patent: September 15, 2020Assignee: 3M INNOVATIVE PROPERTIES COMPANYInventors: Yizhong Wang, Joel D. Oxman, Tiffany Ton
-
Patent number: 10772822Abstract: The invention relates to a molecularly imprinted polymer obtained by polymerization of a mixture comprising a basic ethylene monomer having an amine group, a crosslinking agent comprising at least 2 polymerizable ethylene unsaturations, a porogenic solvent and a C14-C20 fatty acid. A cosmetic composition comprising such a polymer. A cosmetic process to prevent and/or treat dandruff of the scalp using such a polymer.Type: GrantFiled: December 20, 2013Date of Patent: September 15, 2020Assignee: L'OREALInventors: Andrew Greaves, Christèle Ribaud, Franco Manfre, Karsten Haupt
-
Patent number: 10772823Abstract: The invention relates to the use of molecularly imprinted polymer(s) or MIPs, of odorous molecule(s), as deodorant agent in particular for selectively trapping molecules that are the cause of human body odour. More particularly by using MIPs which may be obtained via polymerization, preferably via radical polymerization, of a mixture of: i) optionally one or more polymerization initiator(s); ii) one or more functional monomer(s); iii) one or more crosslinking agent(s); and iv) one or more porogenic solvent(s); it being understood that the polymerization a) or b) is performed in the presence v) of one or more “templates” of target molecule(s) responsible for human body odour. Another subject of the invention concerns a process for preparing MIPs as defined previously, MIPs obtained via this process, and a cosmetic composition comprising at least one MIP as defined previously.Type: GrantFiled: December 16, 2013Date of Patent: September 15, 2020Assignee: L'OREALInventors: Andrew Greaves, Franco Manfre, Karsten Haupt, Jeanne Bernadette Tse Sum Bui
-
Patent number: 10772824Abstract: This invention relates to method of improving the appearance of skin or hair. In particular, it relates to cosmetic products such as creams and serums comprising a subject's own platelet rich plasma (PRP). The invention also relates to kits that allow the user to apply the cosmetic products daily for several days.Type: GrantFiled: June 25, 2019Date of Patent: September 15, 2020Assignee: PPLUS SKIN CARE LIMITEDInventor: Mitra Najafi
-
Patent number: 10772825Abstract: Compositions comprising extracts from marine organisms show beneficial effects on skin ailments. Fine lines, wrinkles, and sagging in skin are improved with the application of compositions with marine extracts. Production of collagen, elastin and hyaluronic acid are increased after application of the compositions.Type: GrantFiled: April 14, 2016Date of Patent: September 15, 2020Assignee: Marine Biology % Environmental Technologies, LLCInventor: Eric Lewis
-
Patent number: 10772826Abstract: A water-insoluble composition, solid in appearance at a temperature of less than or equal to 20° C., comprising, for 100% of the mass of same: —X1% by mass of at least one lipophilic surfactant having a value HLB, H1, greater than or equal to 1 and less than 10; —X2% by mass of at least one hydrophilic surfactant having a value HLB, H2, greater than or equal to 10 and less than or equal to 20; characterised by the fact that the HLB of same=X1.H1+X2.H2, X1 and X2 varying from 2 to 60, and characterised in that it is free of acrylic polymer and/or of acetate succinate.Type: GrantFiled: December 7, 2015Date of Patent: September 15, 2020Assignee: SOCIETE D'EXPLOITATION DE PRODUITS POUR LES INDUSTRIES CHIMIQUES SEPPICInventors: Yves Duccini, Gérard Trouve
-
Patent number: 10772827Abstract: The present invention relates to a nasal administration composition for preventing or treating ischemic cerebrovascular disease, containing a Fas targeting peptide (FTP). When using the pharmaceutical composition or kit of the present invention, a drug can be effectively delivered to brain tissue and the ischemic cerebrovascular disease of a subject can be effectively prevented or treated.Type: GrantFiled: November 14, 2016Date of Patent: September 15, 2020Assignee: INDUSTRY-UNIVERSITY COOPERATION FOUNDATION HANYANG UNIVERSITYInventors: Sang-Kyung Lee, Irfan Ullah, Kun Ho Chung, Jung Ju Oh, Min Hyung Lee, Priti Kumar
-
Patent number: 10772828Abstract: Disclosed herein are compositions and methods for the treatment of otic diseases or conditions with antimicrobial agent compositions and formulations administered locally to an individual afflicted with an otic disease or condition, through direct application of these compositions and formulations onto or via perfusion into the targeted auris structure(s).Type: GrantFiled: March 21, 2013Date of Patent: September 15, 2020Assignees: OTONOMY, INC., THE REGENTS OF THE UNIVERSITY OF CALIFORNIAInventors: Jay Lichter, Andrew M. Trammel, Fabrice Piu, Qiang Ye, Luis A. Dellamary, Carl Lebel, Jeffrey P. Harris
-
Patent number: 10772829Abstract: The invention provides aqueous ophthalmic solutions of phentolamine or pharmaceutically acceptable salts thereof, medical kits, and methods for using such ophthalmic solutions to improve visual performance in a patient. Exemplary aqueous ophthalmic solutions include those containing phentolamine mesylate, mannitol, sodium acetate, and water.Type: GrantFiled: April 30, 2019Date of Patent: September 15, 2020Assignee: Ocuphire Pharma, Inc.Inventor: Alan Meyer
-
Patent number: 10772830Abstract: The present invention relates to a preservative-free, aqueous solution in the form of eye drops packed in a container that ensures stability of the product, ideal eye drop volume and reduced drop volume variability and provides efficient dispensing.Type: GrantFiled: March 26, 2020Date of Patent: September 15, 2020Assignee: PHARMATHEN S.A.Inventors: Evangelos Karavas, Efthimios Koutris, Vasiliki Samara, Ioanna Koutri, Anastasia Kalaskani, Andreas Kakouris, George Gotzamanis
-
Patent number: 10772831Abstract: Provided according to embodiments of the invention pharmaceutical capsules that include a capsule body and a capsule cap, wherein the capsule cap envelops an open end of the capsule body to form a capsule core; and an adherence sheath that envelops a portion of the capsule core. Related capsules and methods of making such capsules are also provided herein.Type: GrantFiled: June 20, 2017Date of Patent: September 15, 2020Assignee: University of Florida Research Foundation, Inc.Inventor: Donn Dennis
-
Patent number: 10772832Abstract: A respirable dry powder including acetylsalicylic acid in particles has a mass median aerodynamic diameter (MMAD) within a range of about 0.5 ?m to about 10 ?m. The respirable dry powder may contain a pharmaceutically acceptable excipient, such as a phospholipid, in an amount ranging from about 0.1% (w/w) to about 10% (w/w) of the particles.Type: GrantFiled: October 30, 2017Date of Patent: September 15, 2020Assignee: OTITOPIC INC.Inventor: Kambiz Yadidi
-
Albumin-CTLA-4 paclitaxel nanopartilce complex compositions and methods of making and using the same
Patent number: 10772833Abstract: Described herein are compositions of antibodies and carrier proteins and methods of making and using the same, in particular, as a cancer therapeutic. Also described are lyophilized compositions of antibodies and carrier proteins and methods of making and using the same, in particular, as a cancer therapeutic.Type: GrantFiled: March 10, 2017Date of Patent: September 15, 2020Assignee: Mayo Foundation for Medical Education and ResearchInventors: Svetomir N. Markovic, Wendy K. Nevala -
Patent number: 10772834Abstract: Provided are a liposome composition in which an osmotic pressure of an inner water phase is 2-fold to 8-fold relative to the osmotic pressure of an outer water phase, and which encapsulates a water-soluble drug in a dissolved state, and also exhibits excellent preservation stability; and a method for producing the same. According to the present invention, it is possible to provide a liposome composition, including liposomes obtained from lipids dissolved and emulsified in an organic solvent, each of which has an inner water phase and an aqueous solution which constitutes an outer water phase and in which the liposomes are dispersed, in which each of the liposomes encapsulates a water-soluble drug in a dissolved state, and an osmotic pressure of the inner water phase is 2-fold to 8-fold relative to the osmotic pressure of the outer water phase; and a method for producing the same.Type: GrantFiled: March 30, 2017Date of Patent: September 15, 2020Assignee: FUJIFILM CorporationInventors: Makoto Ono, Kohei Ono, Takeshi Matsumoto, Mikinaga Mori
-
Patent number: 10772835Abstract: The invention relates to pharmaceutical industry and discloses a method of obtaining a new pharmacologically active liposomal agent containing substances that exhibit specific pharmacological activity on peripheral vessels and cavernous bodies of a mammal. More particularly, the invention relates to a method of obtaining a pharmacologically active liposomal cytochrome c containing nitric oxide. The new liposomal agent acts as a donor of the key biologically active substance—nitric oxide (NO). A method of obtaining a pharmacologically active liposomal cytochrome c and nitric oxide complex comprises the treatment of the liposomal cytochrome c emulsion with gaseous nitric oxide (NO) until liposomal cytochrome c is completely reconstituted and the addition of an S-nitroso compound to the liposomal cytochrome c emulsion.Type: GrantFiled: October 18, 2018Date of Patent: September 15, 2020Inventors: Vitalii V. Prokhorov, Anatoliy I. Solovyov, Oleksandr S. Khromov
-
Patent number: 10772836Abstract: A method for producing particles, the method including: applying vibration to a liquid including a physiologically active substance and included in a liquid-column resonance liquid-chamber to form a standing wave based on liquid column resonance, to thereby discharge the liquid from at least one discharging port, which is formed in an amplitude direction of the standing wave, to at least one region corresponding to at least one anti-node of the standing wave; and drying the liquid discharged, to thereby form particles.Type: GrantFiled: March 2, 2017Date of Patent: September 15, 2020Assignees: RICOH COMPANY, LTD., SHIZUOKA PREFECTURAL UNIVERSITY CORPORATIONInventors: Satomi Onoue, Hideyuki Sato, Yoshiki Seto, Tatsuru Moritani, Tadahiko Morinaga
-
Patent number: 10772837Abstract: The present invention provides modified release pharmaceutical compositions, and methods for administering the compositions to a user, including humans. The composition may contain a combination of ingredients in proportions calculated to achieve therapeutic effect, including at least the following ingredients: one or more natural or synthetic cannabinoids, one or more release modifying agent(s), and one or more pharmaceutically acceptable excipient(s). The composition may be in a multi-layered solid dosage form to provide fast, controlled and also sustained release of specific ingredients. More specifically, the invention relates to modified release pharmaceutical compositions comprising cannabinoids and a process for preparation thereof. More specifically, the invention may control drug release in accordance with the therapeutic purpose and pharmacological properties of active substances.Type: GrantFiled: March 15, 2018Date of Patent: September 15, 2020Assignee: CannTab Therapeutics, LtdInventors: Robert Scott Lefler, Jeff Renwick, Joshi Laxminaraya
-
Patent number: 10772838Abstract: A powdery material mixing degree measurement device includes a discharger configured to discharge mixed powdery materials to a filler configured to fill, with the powdery materials, a vertically penetrating die bore of a compression-molding machine including a table including the die bore, a slidable lower punch including an upper end inserted to the die bore, and a slidable upper punch including a lower end inserted to the die bore, a plurality of movable portions configured to move the mixed powdery materials to the discharger, and a sensor configured to measure a mixing degree of the mixed powdery materials in the movable portions.Type: GrantFiled: February 1, 2017Date of Patent: September 15, 2020Assignee: KIKUSUI SEISAKUSHO LTD.Inventors: Jun Oyama, Naoshige Kitamura, Masaoki Murakoshi
-
Patent number: 10772839Abstract: There is provided a solid pharmaceutical composition for delivering by oral administration a pharmaceutically active binding polypeptide to a region of the intestinal tract comprising a compressed core, wherein the compressed core comprises a pharmaceutically active binding polypeptide and wherein the compressed core is coated with a pH sensitive enteric coating.Type: GrantFiled: September 25, 2018Date of Patent: September 15, 2020Assignee: VHsquared LimitedInventors: Scott Crowe, Mike West, Kevin Roberts, Tim Carlton, Luana Maggiore, Marion Cubitt, Gary Whale, John Wahlich, Mike Frodsham
-
Patent number: 10772840Abstract: Pharmaceutical compositions and methods are provided to treat headache, headache-associated symptoms, photophobia, or adverse effects associated with the headache. Also provided herein are small smooth particulates comprising a 5HT1B/1D receptor agonist. Compositions for oral administration are described herein wherein the compositions comprise a combination of active agents, such as a 5HT1B/1D receptor agonist and one or more antiemetics.Type: GrantFiled: October 2, 2018Date of Patent: September 15, 2020Assignee: CHARLESTON LABORATORIES, INC.Inventors: Paul Bosse, John Ameling, William Kozarek, Bernard Schachtel, John Higgins
-
Patent number: 10772841Abstract: Described herein are abuse deterrent controlled release oral pharmaceutical compositions comprising and methods for making the same. In particular, an abuse deterrent controlled release oral pharmaceutical composition comprising a soft capsule and an abuse deterrent controlled release matrix comprising an active pharmaceutical ingredient are described.Type: GrantFiled: April 6, 2015Date of Patent: September 15, 2020Assignee: PATHEON SOFTGELS INC.Inventors: Saujanya Gosangari, George Vamvakas, Tatyana Dyakonov, Aqeel Fatmi
-
Patent number: 10772842Abstract: Described herein are abuse deterrent controlled release oral pharmaceutical compositions comprising and methods for making the same. In particular, an abuse deterrent controlled release oral pharmaceutical composition comprising a soft capsule and an abuse deterrent controlled release matrix comprising an active pharmaceutical ingredient are described.Type: GrantFiled: October 7, 2015Date of Patent: September 15, 2020Assignee: PATHEON SOFTGELS INC.Inventors: Saujanya Gosangari, Justin Hughey, Tatyana Dyakonov, George Vamvakas, Aqeel A. Fatmi
-
Patent number: 10772843Abstract: The present invention concerns nanoparticles useful for treating posterior segment ocular diseases or conditions, such as macular degeneration and diabetic retinopathy; compositions comprising the nanoparticles; methods for producing the nanoparticles; and methods for treating posterior segment ocular diseases or conditions, comprising administering the nanoparticles or compositions to the ocular posterior segment of an afflicted eye.Type: GrantFiled: May 31, 2018Date of Patent: September 15, 2020Assignee: UNIVERSITY OF SOUTH FLORIDAInventors: Kathleen Emily-Ann Halasz, Yashwant V. Pathak, Vijaykumar Bhadabhai Sutariya
-
Patent number: 10772844Abstract: A hybrid hydrogel including a hydrogel material and a plurality of first hybrid nanoparticles is provided. The plurality of first hybrid nanoparticles are conjugated to the hydrogel material, wherein each of the first hybrid nanoparticles includes a first positive-charged polysaccharide and a first negative-charged polysaccharide. The first positive-charged polysaccharide is located at an inner core of the first hybrid nanoparticles. The first negative-charged polysaccharide is located at an outer shell of the first hybrid nanoparticles and carries a plurality of first growth factors. The first negative-charged polysaccharide and the first positive-charged polysaccharide are electrostatically attracted to form the first hybrid nanoparticles. A method of fabricating the hybrid hydrogel is also provided.Type: GrantFiled: November 5, 2018Date of Patent: September 15, 2020Assignee: National Tsing Hua UniversityInventors: Tzu-Wei Wang, Wei-Hong Jian
-
Patent number: 10772845Abstract: The invention relates to a transdermal therapeutic system (TTS) which is suited for the administration of a peptide to a patient through skin treated with ablation. The transdermal therapeutic system incorporates a back layer and an active substance-containing layer that includes at least one peptide and a carrier substance.Type: GrantFiled: December 2, 2010Date of Patent: September 15, 2020Assignee: LTS Lohmann Therapie-Systeme AGInventors: Michael Horstmann, Horst Dzekan, Sandra Wiedersberg
-
Patent number: 10772846Abstract: Methods and formulations are provided for treating or preventing arthritis, in particular osteoarthritis, where the formulation to be administered to a subject for treating or preventing arthritis comprises carvacrol, curcumin, epigallocatechin-3-gallate and oligomeric procyanidins. The invention provides methods of treating or preventing arthritis, such as osteoarthritis, in a subject in need thereof comprising administering to the subject a formulation or composition comprising carvacrol, curcumin, epigallocatechin-3-gallate and oligomeric procyanidins in an amount effective to treat or prevent arthritis.Type: GrantFiled: November 2, 2015Date of Patent: September 15, 2020Assignees: Montefiore Medical Center, Albert Einstein College of MedicineInventors: Hui B. Sun, Daniel J. Leong, Neil J. Cobelli, David M. Hirsh, John A. Hardin, Karen E. Sperling, Sun Jin Kim, David C. Spray, Chandan Guha, Marwa Choudhury
-
Patent number: 10772847Abstract: Provided herein are formulations that can be effective to kill a pancreatic cancer cell that can include fendiline and a MET inhibitor, an aurora-ABC inhibitor, or an autophagy inhibitor. Also provided herein are methods of treating pancreatic cancer or a symptom thereof in a subject in need thereof, where the method can include the step of administering fendiline and a MET inhibitor, an aurora-ABC inhibitor, or an autophagy inhibitor.Type: GrantFiled: February 20, 2017Date of Patent: September 15, 2020Assignee: UNIVERSITY OF SOUTH FLORIDAInventor: Jaya Padmanabhan
-
Patent number: 10772848Abstract: Disclosed are compositions including phenylephrine, its free and addition salt forms, and mixtures thereof, alone, or in combination with other pharmaceutical actives. The compositions have a pH of about 2 to about 5 and are substantially free of aldehydes. Also disclosed are methods of treating respiratory illness through administration of a composition comprising phenylephrine, its free and addition salt forms, and mixtures thereof alone, or in combination with other pharmaceutical actives, wherein the composition has a pH of from about 2 to about 5 and is substantially free of aldehydes.Type: GrantFiled: August 23, 2018Date of Patent: September 15, 2020Assignee: The Procter & Gamble CompanyInventors: Kelly Lee Schmeichel, Jayant Eknath Khanolkar, Douglas William Gledhill, Susan Elaine Criss, Niranjan Ramji, Elaine Rose Costeines
-
Patent number: 10772849Abstract: This disclosure concerns the discovery of the use of fenoterol analogues for regulating cannabinoid (CB) receptor activity-related disorders and disease, such as dysregulated CB receptors, including treating a disorder or disease, such as a glioblastoma, hepatocellular carcinoma, liver cancer, colon cancer, and/or lung cancer, which is associated with altered cannabinoid receptor activity. In one example, the method includes administering to a subject having or at risk of developing a disorder or disease regulated by CB receptor activity an effective amount of a fenoterol analogue to reduce one or more symptoms associated with the disorder or disease regulated by CB receptor activity.Type: GrantFiled: October 11, 2019Date of Patent: September 15, 2020Assignee: The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Irving W. Wainer, Michel Bernier, Rajib K. Paul
-
Patent number: 10772850Abstract: Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.Type: GrantFiled: April 2, 2020Date of Patent: September 15, 2020Assignee: ANTECIP BIOVENTURES II LLCInventor: Herriot Tabuteau
-
Patent number: 10772851Abstract: Various embodiments disclosed relate to treatment of fungal infections. The present invention provides a method of treating a fungal infection including contacting a fungus including a ?-glucan that is at least partially masked from immune system detection with a therapeutically effective amount of a compound that at least partially unmasks the ?-glucan to increase immunogenicity of the fungus.Type: GrantFiled: February 1, 2018Date of Patent: September 15, 2020Inventors: Aaron Kurt Neumann, Harry Craig Pappas, Matthew Graus, David G. Whitten, Kirk S. Schanze, Rina Sylejmani
-
Patent number: 10772852Abstract: The present invention is directed to combination pharmacological treatments that induce a prolonged, modest decrease in core body temperature, to the range of ?95° F. to ?98.5° F. (?35° C. to ?36.7° C.) to mitigate and delay the early onset and progression of fatal disease processes associated with premature aging, such as those characteristic of progeria (Hutchinson-Gilford Progeria Syndrome, HGPS), Wiedemann-Rautenstrauch syndrome (neonatal progeroid syndrome), Werner syndrome, and other rare disorders characterized by premature aging, and to prolong the shortened lifespan of children afflicted with these diseases. Short-term chronic administration of the pharmaceutical treatments to a person suffering from mild concussion may also have value in ameliorating neurological damage/symptoms associated with mild concussion. Chronic administration of the pharmacological treatments may also have value in normal human populations or in high-risk human populations.Type: GrantFiled: June 12, 2019Date of Patent: September 15, 2020Inventors: Stephen J. Petti, Samn Raffaniello Petti
-
Patent number: 10772853Abstract: The invention provides stable, aqueous capsaicin injectable formulations, a unit dose containing such injectable formulations, medical kits, and methods for using such injectable formulations and unit doses to treat patients suffering from pain, such as osteoarthritic knee pain. The stable, aqueous capsaicin injectable formulations may contain, for example, capsaicin, a solubilizing agent (e.g., a polyethylene glycol ester of a (C15-C25) hydroxyalkanoic acid), an antioxidant, and water.Type: GrantFiled: November 26, 2019Date of Patent: September 15, 2020Assignee: Centrexion Therapeutics CorporationInventors: Drazen Ostovic, Gary Fred Musso
-
Patent number: 10772854Abstract: This disclosure features chemical entities (e.g., a compound exhibiting activity as a mitochondrial uncoupling agent or a pharmaceutically acceptable salt and/or hydrate and/or cocrystal thereof; e.g., a compound, such as niclosamide or a pharmaceutically acceptable salt and/or hydrate and/or cocrystal thereof; e.g., a compound, such as a niclosamide analog, or a pharmaceutically acceptable salt and/or hydrate and/or cocrystal thereof) that are useful, e.g., for treating one or more symptoms of a pathology characterized by an abnormal inflammatory response (e.g., inflammatory bowel diseases) in a subject (e.g., a human). This disclosure also features compositions as well as other methods of using and making the same.Type: GrantFiled: October 29, 2018Date of Patent: September 15, 2020Assignee: First Wave Bio, Inc.Inventors: Gary D. Glick, Luigi Franchi, Giancarlo Santus
-
Patent number: 10772855Abstract: In a method of producing aqueous solutions of N-bromotaurine (Taurine Bromanine, NBrT) with taurine with latter addition of NaOBr, and emulsions of these solutions with Stable Produced Olive Oil (S.P.O.O.), so to use against hyper-proliferative and abnormally differentiating cells of human and mammalian origin. In addition, due to the hyper-proliferation of keratinocytes in psoriatic skin, the methodology and subsequent use of the aqueous solutions and emulsions derived from this invention, containing NBrT and taurine, and S.P.O.O. against the lesions of psoriasis. With the method of this invention, the solutions derived and applied on cells in vitro beneficially provide maximization of NBrT anti-proliferative properties on abnormally differentiating and hyper-proliferating cells of human and mammalian origin by restoring NBrT anti-proliferative activity in a solution, whilst leaving unaffected the proliferation of normally dividing human fibroblasts.Type: GrantFiled: February 17, 2017Date of Patent: September 15, 2020Inventor: Antonios Kyriakopoulos
-
Patent number: 10772856Abstract: The present invention provides a composition comprising HMB. Methods of administering HMB to an animal are also described. HMB is administered to enhance or promote lipolysis, increase adipocyte fat oxidation, induce adipocyte and muscle mitochondrial biogenesis, increase energy expenditure, decrease total body weight and increase body fat loss.Type: GrantFiled: December 13, 2017Date of Patent: September 15, 2020Assignee: Metabolic Technologies, Inc.Inventors: John Rathmacher, Naji Abumrad, Shawn Baier
-
Patent number: 10772857Abstract: Highly concentrated solutions are disclosed along with methods of inhibiting and/or ameliorating functional neurological disorders of the brain. The method may include administering directly to a brain of a subject a medicament multiple times over a time period of at least two days. The medicament may include a half-life of less than 2 hour in the cerebrospinal fluid. The method may include inhibiting and/or ameliorating a functional neurological disorder of the brain using the medicant.Type: GrantFiled: October 23, 2018Date of Patent: September 15, 2020Assignee: Cerebral Therapeutics, Inc.Inventors: Daniel J. Abrams, Thomas Joseph Anchordoguy
-
Patent number: 10772858Abstract: This disclosure relates to benzhydrol derivatives for managing conditions related to the Hypoxia Inducible Factor (HIF) pathway such as uses in treating cancer. In certain embodiment, the disclosure contemplates compounds and pharmaceutical compositions. In certain embodiment, the disclosure contemplates compounds disclosed herein as prodrugs, optionally substituted with one or more substituents, derivatives, or salts thereof.Type: GrantFiled: May 2, 2016Date of Patent: September 15, 2020Assignees: GEORGIA STATE UNIVERSITY RESEARCH FOUNDATION, INC., EMORY UNIVERSITYInventors: Binghe Wang, Erwin Van Meir, Jalisa Holmes Ferguson, Stefan Kaluz, Xingyue Ji
-
Patent number: 10772859Abstract: Methods for targeting apurinic/apyrimidinic endonuclease1/redox effector factor 1 (APE1/Ref-1) are disclosed. More particularly, methods for inhibiting APE1/Ref-1 and hypoxia-mediated signaling for decreasing survival and invasion of tumor cells exposed to hypoxic conditions are disclosed.Type: GrantFiled: May 5, 2016Date of Patent: September 15, 2020Assignee: Indiana University Research and Technology CorporationInventors: Mark R. Kelley, Melissa Fishel
-
Patent number: 10772860Abstract: This disclosure provides generally for antimicrobial compositions and methods of use comprising an anthocyanin, an anthocyanidin or metabolites thereof. Methods for promoting healing of a wound using these compositions are also disclosed. These compositions have broad spectrum antimicrobial activity and are safe for human and animal uses. Further, these compositions are safe for medical uses and industrial uses as antiseptic preparations to reduce or prevent microbial growth, including killing bacterial biofilms.Type: GrantFiled: October 1, 2019Date of Patent: September 15, 2020Inventor: Lanny Leo Johnson
-
Patent number: 10772861Abstract: The inventors have unexpectedly discovered that shock and/or potential multi-organ failure due to shock can be effectively treated by administration of liquid high-dose protease inhibitor formulations to a location upstream of where pancreatic proteases are introduced into the gastrointestinal tract. Most preferably, administration is directly to the stomach, for example, via nasogastric tube under a protocol effective to treat shock by such administration without the need of providing significant quantities of the protease inhibitor to the jejunum and/or ileum.Type: GrantFiled: November 21, 2018Date of Patent: September 15, 2020Assignees: Leading Biosciences, LLC, The Regents of the University of CaliforniaInventors: Geert W. Schmid-Schonbein, Yung-Tsai (Andrew) Lee, Jeng Wei
-
Patent number: 10772862Abstract: Methods and compositions for treating Ras-related cancers are provided that involve targeting lipid scavenging. Methods and compositions for identifying and/or characterizing more or less responsive cancers are also provided.Type: GrantFiled: October 15, 2018Date of Patent: September 15, 2020Assignees: The Trustees of Princeton University, Memorial Sloan Kettering Cancer CenterInventors: Joshua Rabinowitz, Jurre Kamphorst, Craig Thompson, Justin Cross
-
Patent number: 10772863Abstract: Provided are methods of increasing metabolic maturation of an immature hepatocyte, by contacting an immature hepatocyte which expresses alpha-fetoprotein (AFP) and albumin with an effective amount of a fatty acid or a small molecule selected from the group consisting of: an amphipathic carboxylic acid, Thiazolidinedione (TZD), WY-14643 (Pirinixic Acid), GW409544, GW6471, Leukotriene B4, GW 7647, Perfluorooctanesulfonic Acid, Perfluorooctanoic Acid, CP-775146, CP-865520, UNII-999KY5ZIGB, and Gemfibrozil. Also provided are isolated hepatocytes and uses thereof.Type: GrantFiled: March 15, 2017Date of Patent: September 15, 2020Assignee: Yissum Research Development Company of the Hebrew University of Jerusalem LtdInventors: Yaakov Nahmias, Michal Zimerman, Gahl Levy, Yishai Avior
-
Patent number: 10772864Abstract: Methods and compositions containing a phorbol ester or a derivative of a phorbol ester are provided for the treatment of chronic and acute conditions. Such conditions may be caused by disease, be symptoms or sequalae of disease. Chronic and acute conditions may be due to viral infections such as HIV and AIDS, neoplastic diseases stroke, kidney disease, urinary incontinence, autoimmune disorders, Parkinson's disease, prostate hypertrophy, aging, or the treatment of such diseases. Additional compositions and methods are provided which employ a phorbol ester or derivative compound in combination with at least one additional agent to yield more effective treatment tools against acute and chronic conditions in mammalian subjects.Type: GrantFiled: February 25, 2019Date of Patent: September 15, 2020Assignee: Biosuccess Biotech Co., Ltd.Inventors: Hung-Fong Chen, Zheng Tao Han
-
Patent number: 10772865Abstract: The present invention relates to methods for treating a disease associated with insulin resistance selected from a nonalcoholic fatty liver disease (NAFLD) and its sequelae, a lipodystrophic syndrome or a combination thereof with the selective PPAR? agonist, INT131 and optionally vitamin E or compositions thereof. NAFLDs that may be treated with methods and compositions of the present invention include, but are not limited to, simple nonalcoholic fatty liver and nonalcoholic steatohepatitis (NASH). Lipodystrophic syndromes that may be treated with the methods and compositions of the present invention include, but are not limited to, generalized lipodystrophy including congenital generalized lipodystrophy and acquired generalized lipodystrophy and/or partial lipodystrophy, including congenital partial lipodystrophy and acquired partial lipodystrophy, all of which may or may not include hyperlipidemia and/or hyperglycemia and may or may not include NAFLD.Type: GrantFiled: January 16, 2020Date of Patent: September 15, 2020Assignee: Coherus Biosciences, Inc.Inventor: Christos Mantzoros